Project Grant HT94252510156
Award Date
5/1/25
Completion Date
4/30/28
Dollars Obligated
$803K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This federal Project Grant award for $614,936.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), is supporting research at Baylor College of Medicine to investigate the clinical and genetic factors underlying autism spectrum disorder among individuals with tuberous sclerosis complex. The research aims to advance the understanding of the relationship between these two conditions, with the ultimate goal of improving diagnostic...
This $1,171,770.00 Project Grant, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research at Baylor College of Medicine to investigate brain representations of language in children with tuberous sclerosis complex. The award period is from July 1, 2024 to June 30, 2027. Tuberous sclerosis complex is a rare genetic disorder that can cause neurological symptoms, making this a critical area of medical research. The findings...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $148,942 to the Westfaelische Wilhelms-Universitaet Muenster in Germany to conduct research on identifying and characterizing the guanine nucleotide exchange factor (GEF) for the small GTPase Rheb as a novel target for treating tuberous sclerosis complex (TSC). The two-year award, running from July 1, 2024 to June 30, 2026, will support the university's...
This federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $1,759,500.00 to Baylor College of Medicine in Houston, Texas to support research aimed at "Creating Cures for Patients with Langerhans Cell Histiocytosis." The award, which runs from September 1, 2024 to August 31, 2028, will enable Baylor to conduct innovative biomedical studies to develop new treatments and therapies for this rare genetic...
This $703,000 Project Grant award was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to the Research Institute at Nationwide Children's Hospital in Columbus, Ohio. The grant supports the preclinical development of a micro-tuberin gene therapy for the treatment of Tuberous Sclerosis Complex Type 2. The award began on April 1, 2025 and is scheduled for completion on March 31, 2027. As a non-profit research organization, the...
This federal Project Grant award of $2,239,998.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by Baylor College of Medicine to investigate the progression from ductal carcinoma in situ (DCIS) to invasive basal-like breast cancer driven by the N-RAS gene. The research project aims to advance the understanding of this disease process with the potential to lead to improved diagnostic and treatment approaches. The...
This $772,626 Project Grant award from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) supports preclinical validation of gene therapy in mouse models of tuberous sclerosis complex (TSC) and lymphangioleiomyomatosis (LAM) at Brigham & Women's Hospital. The grant, with a performance period from August 1, 2025 to July 31, 2028, will enable the hospital's biomedical researchers to advance the development of innovative gene therapy interventions for these...
The Department of the Army Medical Command awarded a $1,715,894 project grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program. The grant will fund research from August 1, 2022 to July 31, 2025 to target tuberous sclerosis complex (TSC) by developing mTORC1-specific bi-steric inhibitors.
The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming military and...
This federal Project Grant award of $1,597,224.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to support research conducted by Baylor College of Medicine in Houston, Texas. The award period runs from August 1, 2024 to July 31, 2027.
The grant is funding research into the role of the BCL-XL protein in breast cancer metastasis and potential therapies. Baylor College of Medicine, a leading academic medical center, will...
The U.S. Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $739,720 Project Grant to Baylor College of Medicine on June 1, 2024. The grant supports the "Development of Lead Compounds that Promote Telomere Elongation to Prevent and Treat Bone Marrow Failure in the Telomere Biology Disorders" over a 2-year period ending May 31, 2026. This research aims to develop new medical treatments for rare genetic conditions affecting...